Table 4 Consensus items from the Delphi survey

DOMAIN 1. Persistent negative symptoms

Round 1

Q1

In the management of an adult patient with schizophrenia presenting with blunted affect associated with residual psychotic symptoms unimproved by current SGA treatment, a switch from the current SGA to aripiprazole is a relevant treatment option

Round 1

Q3

In the management of an adult patient with schizophrenia presenting with blunted affect associated with psychomotor retardation unimproved by current SGA treatment, a switch from the current SGA to aripiprazole is a relevant treatment option:

Round 1

Q4

In the management of an adult patient with schizophrenia presenting with blunted affect associated with anxiety unimproved by current SGA treatment, aripiprazole in association with the current SGA is NOT a relevant treatment option:

Round 1

Q5

In the management of an adult patient with schizophrenia presenting with blunted affect associated with social withdrawal unimproved by current SGA treatment, a switch from the current SGA to aripiprazole is a relevant treatment option:

Round 1

Q1

In the management of an adult patient with schizophrenia presenting with blunted affect associated with other negative symptoms partially responsive to the current SGA, addition of aripiprazole in combination with the antipsychotic is NOT a more relevant treatment option than aripiprazole in monotherapy

Round 1

Q2

In the management of an adult patient with schizophrenia presenting with blunted affect associated with depressed mood partially responsive to the current SGA, aripiprazole is a relevant treatment after the failure of combining the current SGA with an antidepressant

DOMAIN 2. Pregnancy

Round 1

Q3a

Maintenance of oral aripiprazole is an appropriate option in a well-controlled adult patient who discovers her pregnancy during the first trimester

Round 1

Q5

Maintenance of oral aripiprazole is an appropriate option in an adult patient throughout the duration of her pregnancy right up to delivery

Round 2

Q1a

In an adult patient well-controlled on oral aripiprazole who finds herself pregnant, aripiprazole treatment should be maintained

Round 2

Q1b

In an adult patient well-controlled on oral aripiprazole who is planning a pregnancy, aripiprazole treatment should be maintained

Round 2

Q2b

In an adult patient well-controlled on depot aripiprazole who is planning a pregnancy, aripiprazole treatment does not need to be switched to the oral formulation of aripiprazole

DOMAIN 3: COGNITIVE DYSFUNCTION

Round 1

Q1

In the management of an adult patient with schizophrenia, aripiprazole is a relevant treatment option to preserve cognitive function

Round 1

Q6

In the management of an adult patient with schizophrenia presenting with cognitive problems appearing during treatment with the current antipsychotic, a switch to aripiprazole is a relevant treatment option if the patient is treated with an FGA

Round 2

Q2

In the management of an adult patient with schizophrenia presenting with cognitive problems appearing during treatment with the current antipsychotic, a switch to aripiprazole is a relevant treatment option

DOMAIN 4: ADDICTIVE COMORBIDITY

Round 1

Q1

Aripiprazole is an appropriate option in an adult with schizophrenia and a comorbid addictive disorder

Round 1

Q5

Aripiprazole is an appropriate option for treatment of a first psychotic episode in a patient with a comorbid cannabis use disorder

Round 2

Q1

In an adult patient well-controlled on another antipsychotic who has an unresolved addictive disorder, add-on aripiprazole treatment is NOT an appropriate option

Round 2

Q2a

In an adult patient not controlled on another antipsychotic who has an unresolved addictive disorder, switching to aripiprazole treatment is a relevant therapeutic alternative

Round 1

Q2

In the management of an adult patient with schizophrenia with clozapine resistance, aripiprazole is a relevant treatment option if negative symptoms persist

Round 2

Q1

In the management of an adult patient with schizophrenia presenting a partial response to clozapine, aripiprazole is a relevant treatment option